Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2663 results

Media Release / Jun 29, 2016
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…
Media Release / Jul 14, 2016
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Presbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1] Dailies Total1® Multifocal contact lenses provide a seamless visual experience…
Media Release / Jul 13, 2016
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product …
Media Release / Jul 19, 2016
Novartis erzielt im 2. Quartal solide Ergebnisse trotz US-Generikakonkurrenz für Gleevec im gesamten Quartal; wichtige positive Neuigkeiten zu Innovationen stärken zukünftige Wachstumsperspektiven
Der Nettoumsatz bleibt im zweiten Quartal unverändert (0% kWk[1]), da die Wachstumsprodukte[2] die Einbussen durch Generikakonkurrenz für Gleevec kompensieren Gilenya (USD 811 Millionen, +17%…
Media Release / Jul 19, 2016
Novartis réalise un 2ème trimestre solide, malgré l'impact sur le trimestre du générique de Gleevec aux US; nouvelles positives importantes de l'innovation renforcent les perspectives de croissance
Chiffre d'affaires net du T2 stable (0% tcc[1]), les produits de croissance[2] ayant compensé l'impact du générique de Gleevec Gilenya (USD 811 millions, +17% tcc) a continué de croître à un taux…
Media Release / Jul 19, 2016
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (…
Media Release / Aug 03, 2016
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Designation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer population and the potential of LEE011 (ribociclib) as an effective new treatment option Results…
Media Release / Aug 02, 2016
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…
Media Release / Aug 25, 2016
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression…
Media Release / Aug 15, 2016
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
The Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and Harald von Boehmer for demonstrating that the ability of the immune system to discriminate "self" from "non-self" is…